Novocure reports Q4 net loss $47.1M, full year revenue down 5%; NSCLC PMA accepted

NovoCure Ltd

2023-FY EPS reported -$1.95 revenue$509,338,000

Full year 2023 net revenues $509.3M, down 5% YoY; Q4 net revenues $133.8M, up 4% YoY.
Q4 net loss $47.1M ($0.45 loss per share); adjusted EBITDA -$31.6M.
Active patients 3,755 (+9% YoY); prescriptions 1,564 (+14% YoY).
FDA accepted PMA for TTFields in NSCLC; enrollment completed in phase 3 TRIDENT trial.
Cash, cash equivalents and short-term investments $910.6M as of Dec 31, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NovoCure Ltd reported the fiscal year ended December 31, 2023 results: revenue $509.3 million.

Period: the fiscal year ended December 31, 2023
Revenue: $509.3 million
Result: reported results

Exact text from the filing

Total net revenues for the year were $509.3 million, a decrease of 5% year-over-year.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NovoCure Ltd reported the quarter ended December 31, 2023 results: revenue $133.8 million, net income Net loss for the quarter was $47.1 million, EPS loss per share of $0.45.

Period: the quarter ended December 31, 2023
Revenue: $133.8 million
Net income: Net loss for the quarter was $47.1 million
EPS: loss per share of $0.45
Result: reported results

Exact text from the filing

Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update Full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million PMA application for TTFields in NSCLC accepted for review by U.S. Food and Drug Administration Enrollment completed in phase 3 TRIDENT trial studying the use of TTFields therapy

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

NovoCure Ltd filing history →

Source: SEC EDGAR

accession 0001645113-24-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.